NCT07282743ClinicalTrials.gov

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of GL0034 Among Type II Diabetes Mellitus Subjects Who Are Obese or Overweight With Weight-related Comorbidities

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.

Diese Studie kontaktieren

Kurz gefasst

Phase 2285 Teilnehmende gesucht21 Studienzentren2 Länder

Kategorien

Endokrin und metabolisch100%

In 1 Register registriert

ClinicalTrials.govNCT07282743Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert vor 2 Monaten

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Present: Registered before enrolment beganFirst posted 2025-12-15; recorded start 2026-01-20
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Present: Participants are randomly assignedAllocation is recorded as randomised
Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
Present: Uses blinding (masking)A masking level is recorded in the record
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 67 other studies in this databaseCounted from the lead sponsor named in the record (Sun Pharmaceutical Industries Limited)
Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.
Intervention regulatory context: investigational, within a phased regulatory pathway.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation20/20
Participants are randomly allocated between arms
Blinding16/20
Triple-blind
Control arm13/15
Placebo / sham control arm
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 21 sites
Data monitoring committee0/7
Data monitoring committee not stated in the record
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 285 participants (target), run at 21 sites, across 2 countries.

How this score is built

Enrolment24/40
285 participants (target)
Site count16/25
21 sites
Country count7/15
2 countries
Planned duration6/10
Planned over about 19 months
Sponsor scale7/10
Sun Pharmaceutical Industries Limited has led 65 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, once a week, subcutaneous injection) or placebo arm (once a week, subcutaneous injection) following initial dose-up titration that takes up to approximately 20 weeks. The primary end point is change in HbA1c levels from baseline (Week 0) to Week 36 following treatments in all participants.

Erkrankungen

Type II Diabetes Mellitus

Eignung

Eignung
Geschlecht	Alle
Alter	18 Years – Kein Höchstalter
Gesunde Freiwillige	Nein

Eignung im Wortlaut des Registers

Inclusion Criteria: 1. Participant is willing and able to sign a written ICF or e-ICF. 2. Men or women ≥18 years of age at the time of signing ICF or e-ICF. 3. Participant was diagnosed with type II diabetes mellitus at least 180 days prior to the day of screening. 4. Participant has a HbA1c level of 7.0 - 10.5%, both inclusive, at the time of screening. 5. Participant has a stable BMI ≥27 kg/m2 for at least 90 days prior to screening. 6. Participant is able and willing to undergo fasting blood draw (i.e. at least 8 hours after last eating or drinking) as well as 7-point SMBG check for 3 consecutive days prior to designated scheduled visits by using a home glucometer that is provided by the study site. 7. Participant on stable daily doses of metformin for at least 90 days prior to screening. 8. Participant who are on metformin and not the following agents for at least 3 months prior to screening: DPP-4 inhibitors, alpha-glucosidase enzyme inhibitors, sulfonylureas, sodium-glucose transport 2 inhibitors, amylin analogues, thiazolidinediones, any insulin product, herbals, or ayurvedic agents. Participants are encouraged to follow the standard of care in their study regions, including appropriate diet and lifestyle modifications, rather than make abrupt change in the diabetic management prior to screening without consulting their physicians. 9. If participant is a woman of childbearing potential (WOCP)\*, she must agree to use a highly effective method of contraception during the study in conjunction with a barrier method of contraception, and continue the same contraception method at least one months after the last dose of study drug. Highly effective methods of contraception include one of the following: intrauterine device, injectable hormonal contraceptive, contraceptive patch or implant, partner's vasectomy, bilateral tubal occlusion, and sexual abstinence. \*WOCP includes women who are not surgically sterilized \[using hysterectomy/bilateral salpingectomy/bilateral oophorectomy\] or post-menopausal \[defined as 12 consecutive months of amenorrhea without an alternative medical cause\]. 10. Male participants with female partners of child-bearing potential must use a barrier method of contraception (e.g., condom) if not surgically sterile (i.e., vasectomy) during the study. In addition, male participants agree to use the same method of contraception for an additional 30 days after the last IP dose and refrain from donating sperm during this period. In the event that the female partner of the male participant becomes pregnant during the study period + 30 days after the last IP dose, an ICF will be provided to the female partner in order to monitor the female partner, pregnancy, and the newborn. 11. If participant is a WOCP, she must have a negative serum pregnancy test (SPT) at Screening and a negative urine pregnancy at baseline, with results available before IP administration. 12. Participant is willing and able to comply with the study protocol, visit schedule, and other study-related instructions and procedures. 13. Participant is willing and able to independently record the response on various scales and make entries using the e-Patient reported outcomes (ePRO) device. Exclusion Criteria: 1. Participants who have a history of type I diabetes mellitus. 2. A self-reported change in \>5% of body weight within 90 days before screening irrespective of medical records. 3. History of pancreatitis (acute or chronic) or \>3 hypoglycemic episodes (blood glucose level \<70 mg/dL or 3.9 mmol/L) within 90 days prior to screening. 4. Diagnosis of chronic kidney disease with estimated glomerular filtration rate \<60. 5. Poorly controlled hypertension with systolic blood pressure \>160 mmHg and/or diastolic blood pressure \>100 mmHg. 6. Poorly controlled hypothyroidism defined as thyroid-stimulating hormone \>6 mIU/L or \<0.4 mIU/L. 7. Diabetes mellitus and/or obesity that is induced by endocrine disorders (e.g. Cushing Syndrome) or medication use (e.g. corticosteroids) as judged by the Investigator. 8. Previous surgical treatment for obesity (liposuction and/or abdominoplasty performed \>1 year before screening is allowed). Previous or planned (during the trial period) obesity treatment with surgery or a weight loss device. However, previous interventions that, due to reversal or removal, does not have any influence on the participant's weight, in the opinion of the Investigator, are allowed. 9. History of major depressive disorder within 2 years before randomization. 10. History of other severe psychiatric illnesses (i.e. schizophrenia, bipolar disorder). 11. Any lifetime history of a suicidal attempt. 12. Participants with any medical condition \[i.e. gastroparesis, uncontrolled gastroesophageal reflux disease, or diarrhea with or without a diagnosis of a diagnosis of irritable bowel syndrome\] that, in the opinion of the Investigator, can confound study efficacy assessments or safety concerns. 13. Participant had a myocardial infarction, unstable angina pectoris, or ischemic stroke within the past 6 months prior to IP administration. 14. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, sudden cardiac death, unexplained death, long QT syndrome, or death from a primary dysrhythmia potentially associated with QT prolongation in any family member. 15. Surgery scheduled for the trial duration period, except for very minor surgical procedures in the opinion of the Investigator. 16. Participants with active malignancy. Note: participants with past history of malignancy may be included if: * Participant has history of basal cell or in-situ squamous cell carcinoma of skin that has been adequately treated and resolved, per Investigator's judgement. * Participant has history of other malignancy that have been adequately treated with no evidence of recurrence/relapse within the last 5 years, per Investigator's judgement. 17. Presence of diabetic retinopathy \[both nonproliferative diabetic retinopathy and proliferative diabetic retinopathy\]) or maculopathy in either eye that was verified by a fundoscopic examination within 90 days prior to screening or during the study. 18. Known moderate to severe coronary, carotid, or peripheral vascular disease that has planned or will likely need revascularization during the study. 19. Participants with any other condition, which in the opinion of the Investigator, precludes participation in the study (either poses an unacceptable risk to the participant or interferes with assessment/interpretation of study outcomes). 20. Known hypersensitivity to the study IP or its excipients. 21. History of alcohol or drug abuse in the previous two years (Alcohol abuse in this study is defined as \>14 standard drinks per week in men or \>7 standard drinks per week in women ± a history of alcohol withdrawal symptoms ± institutionalized/hospitalized due to alcohol use ± binge drinking with \>5 standard drinks on a single occasion in men or \>4 standard drinks on a single occasion in women). 22. Participants are taking, or will start, medications with narrow therapeutic index such as digoxin, warfarin, etc, or those that will prolong QTc interval. 23. Participants received any medications for the treatment of type II diabetes mellitus other than those stated in the inclusion criteria within 90 days before screening. Short-term insulin treatment for a maximum of 7 days prior to screening is allowed. Prior insulin treatment for gestational diabetes is also allowed. 24. Participants who have used medications in the family of GLP-1 agonists in the past. 25. Treatment with any herbal diet supplements, over-the-counter diet medications as an attempt to lose weight within 90 days before screening. 26. Treatment with orlistat, lorcaserin, zonisamide, topiramate, phentermine, buproprion, or naltrexone that could promote weight loss within 90 days before screening. 27. Participation in any organized or online weight-reduction program (i.e. Weight Watchers) within 90 days before screening. 28. Screening calcitonin ≥50 ng/L (pg/mL). 29. Participants having clinically significant abnormal values on Screening laboratory tests or other evidence of uncontrolled disease involving any system-organ (e.g., cardiovascular, pulmonary, renal, hepatic, neurological, endocrine, gastrointestinal, psychiatric etc.) that, in the opinion of the Investigator, would put the participant at risk by participating in the study. 30. Participants with positive urine drug screen \[amphetamine, barbiturate, benzodiazepine, cocaine, opiates\] with substances that are not part of participant's routine medical care. Tetrahydrocannabinols is acceptable for as long as its use is legally allowed by participant 's home state or country. 31. Participants have clinically significant ECG abnormality , including QTcF \>450 msec for males and \>470 msec for females, or at high risk for arrhythmia such as judged by the Investigator conditions listed in Criteria #13 above, brady-arrhythmias, tachy-arrhythmias, ventricular arrhythmias, torsade de pointes, high-degree atrioventricular block, or New York Heart Association Class III and IV congestive heart failure. 32. Pregnant or lactating females.

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
Studientyp	Interventionell
Phase	Phase 2
Zuteilung	Randomisiert
Interventionsmodell	PARALLEL
Primäres Ziel	TREATMENT
Verblindung	TRIPLE (3)
Teilnahme	285 Teilnehmende gesucht

Sponsor und Mitwirkende

Sun Pharmaceutical Industries Limited Sponsor

Studienarme und Interventionen

Arm 1EXPERIMENTAL
Dose Up-titration Period: Participants receive GL0034 starting at Dose Level 1 with titration up to Dose Level 2 for approximately 20 weeks Maintenance Treatment Period: Once participants reach their final designated doses, they will continue to receive the final designated doses by weekly subcutaneous administration until the end of Week 48.
Arm 2EXPERIMENTAL
Dose Up-titration Period: Participants receive GL0034 starting at Dose Levels 1 to 3 with titration up to Dose Level 2 for approximately 20 weeks Maintenance Treatment Period: Once participants reach their final designated doses, they will continue to receive the final designated doses by weekly subcutaneous administration until the end of Week 48.
Arm 3EXPERIMENTAL
Dose Up-titration Period: Participants receive GL0034 starting at Dose Levels 1 to 4 with titration up to Dose Level 2 for approximately 20 weeks Maintenance Treatment Period: Once participants reach their final designated doses, they will continue to receive the final designated doses by weekly subcutaneous administration until the end of Week 48.
Arm 4EXPERIMENTAL
Dose Up-titration Period: Participants receive GL0034 starting at Dose Levels 1 to 6 with titration up to Dose Level 2 for approximately 20 weeks Maintenance Treatment Period: Once participants reach their final designated doses, they will continue to receive the final designated doses by weekly subcutaneous administration until the end of Week 48.
PlaceboPLACEBO_COMPARATOR
Dose Up-titration Period: Participants receive sham placebo up titration, once weekly for approximately 20 weeks. Maintenance Treatment Period: Participants will continue to receive placebo once weekly through subcutaneous administration until the end of Week 48.

Interventionen

Arzneimittel GL0034 Dose Level 1
Dose 1, once a week
Arzneimittel GL0034 Dose Level 2
Dose 2, once a week
Arzneimittel GL0034 Dose Level 3
Dose 3, once a week
Arzneimittel GL0034 Dose Level 4
Dose 4, once a week
Arzneimittel GL0034 Dose Level 5
Dose 5, once a week
Arzneimittel GL0034 Dose Level 6
Dose 6, once a week
Sonstige Placebo
Placebo, once a week

Endpunkte

Primärer Endpunkt
Change in HbA1c levels from baseline (Week 0) to Week 36 following treatments in all participants
Zeitrahmen Week 36
Sekundärer Endpunkt
Number of participants with an HbA1c <7.0%, <6.5%, or <5.7%
Zeitrahmen Week 36 or Week 48
Sekundärer Endpunkt
Change in HbA1c levels from baseline (Week 0) to Week 48 following treatments in all participants
Zeitrahmen Week 48
Sekundärer Endpunkt
Change in HbA1c levels over time from baseline (Week 0) to Week 48 following treatments in all participants
Zeitrahmen Week 48
Sekundärer Endpunkt
Percent change (%) in body weight and BMI from baseline (Week 0) to Week 36, Week 48, and over time from baseline to Week 48 following treatments in all participants.
Zeitrahmen Week 36 and Week 48
Sekundärer Endpunkt
Percent of participants who achieved ≥5%, ≥10%, ≥15%, >20%, >25% weight loss from baseline to Week 36 or Week 48 of treatments in all participants.
Zeitrahmen Week 36 or Week 48

Daten

Daten
Startdatum	20. Januar 2026 (tatsächlich)
Primärer Abschluss	1. April 2027 (geschätzt)
Abschluss	1. August 2027 (geschätzt)
Erstveröffentlichung	15. Dezember 2025 (tatsächlich)
Zuletzt aktualisiert	18. März 2026
Ergebnisse veröffentlicht	Im Registereintrag nicht angegeben
Status zuletzt bestätigt	März 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

21 Studienzentren rekrutieren

India

India
Einrichtung	Stadt	Bundesland oder Region	Status
Life Care Hospital and Research Centre	Bangalore	Karnataka	Rekrutiert
Madras Diabetes Research Foundation (MDRF)	Chennai	Tamil Nadu	Rekrutiert
Endolife Specialty Hospitals Pvt. Ltd.	Guntur	Andhra Pradesh	Rekrutiert
Nirmal Hospital Private Limited	Kolhāpur	Maharashtra	Rekrutiert
Government Medical College	Kozhikode	Kerala	Rekrutiert
BSES Municipal General Hospital	Mumbai	Maharashtra	Rekrutiert
Seth G. S. medical college and KEM hospital	Mumbai	Maharashtra	Rekrutiert
Topiwala National Medical College & BYL Nair Hospital	Mumbai	Maharashtra	Rekrutiert
All India Institute of Medical Sciences	New Delhi	National Capital Territory of Delhi	Rekrutiert
Lady Hardinge Medical College and S.S.K. Hospital	New Delhi	National Capital Territory of Delhi	Rekrutiert
LMMF's Deenanath Mangeshkar Hospital and Research Center	Pune	Maharashtra	Rekrutiert
Jothydevs Diabetes Research Centre	Trivandrum	Kerala	Rekrutiert

United States

United States
Einrichtung	Stadt	Bundesland oder Region	Status
AMR Clinical, El Dorado	El Dorado	Kansas	Rekrutiert
Family First Medical Research Center	Hialeah Gardens	Florida	Rekrutiert
Alliance for Multispecialty Research (AMR Clinical) - Wichita East	Lakeland	Florida	Rekrutiert
CNS Healthcare - Memphis (Clinical Neuroscience Solutions - Memphis)	Lakeland	Florida	Rekrutiert
Lynn Institute of the Ozarks	Little Rock	Arkansas	Rekrutiert
GTL Medical & Research Group	Miami	Florida	Rekrutiert
AMR Clinical - Newton	Newton	Kansas	Rekrutiert
Lynn Health Science Institute - Oklahoma City	Oklahoma City	Oklahoma	Rekrutiert
Florida Institute for Clinical Research LLC	Orlando	Florida	Rekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

Seit wir diesen Eintrag erstmals eingelesen haben, wurden keine Änderungen erfasst.

Eine Änderung wird jedes Mal erfasst, wenn der Sponsor den Registereintrag aktualisiert. Status, Daten, Teilnahme und Studienzentren erscheinen hier, sobald sie sich ändern.

https://xmedica.io/trials/ctgov/NCT07282743